Merger Scrutiny A Bigger Risk To Pharma Than Drug Price Reform, Orzag Predicts

 
• By Jessica Merrill
  
US M&A scrutiny could be an overhang for pharma • Source: Alamy

More from Pricing Debate

More from Market Access